WO2022251516A3 - Complexes à chélateurs acycliques et leur utilisation en radiothérapie ciblée de cancer - Google Patents

Complexes à chélateurs acycliques et leur utilisation en radiothérapie ciblée de cancer Download PDF

Info

Publication number
WO2022251516A3
WO2022251516A3 PCT/US2022/031157 US2022031157W WO2022251516A3 WO 2022251516 A3 WO2022251516 A3 WO 2022251516A3 US 2022031157 W US2022031157 W US 2022031157W WO 2022251516 A3 WO2022251516 A3 WO 2022251516A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
compounds
solvate
complexes
pharmaceutically acceptable
Prior art date
Application number
PCT/US2022/031157
Other languages
English (en)
Other versions
WO2022251516A2 (fr
Inventor
Justin J. Wilson
Joshua J. WOODS
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of WO2022251516A2 publication Critical patent/WO2022251516A2/fr
Publication of WO2022251516A3 publication Critical patent/WO2022251516A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/30—Metal salts; Chelates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente technologie concerne des composés, ainsi que des compositions comprenant de tels composés, utiles en radiothérapie ciblée (par exemple, une thérapie à l'uranium) de cancer et/ou de tissu de mammifère surexprimant, par exemple, un antigène ou un récepteur, les composés étant représentés par les formules suivantes ou par un de leurs sels et/ou solvates pharmaceutiquement acceptables, M1 étant indépendamment, à chaque occurrence, un radionucléide. L'invention divulgue également des équivalents de tels composés.
PCT/US2022/031157 2021-05-26 2022-05-26 Complexes à chélateurs acycliques et leur utilisation en radiothérapie ciblée de cancer WO2022251516A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163193434P 2021-05-26 2021-05-26
US63/193,434 2021-05-26

Publications (2)

Publication Number Publication Date
WO2022251516A2 WO2022251516A2 (fr) 2022-12-01
WO2022251516A3 true WO2022251516A3 (fr) 2023-01-26

Family

ID=84230354

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/031157 WO2022251516A2 (fr) 2021-05-26 2022-05-26 Complexes à chélateurs acycliques et leur utilisation en radiothérapie ciblée de cancer

Country Status (1)

Country Link
WO (1) WO2022251516A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206606A1 (en) * 2003-07-24 2011-08-25 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for preparation
US20150238641A1 (en) * 2012-09-13 2015-08-27 British Columbia Cancer Agency Branch Compositions targeting bradykinin receptor b1 for medical imaging of cancer and other disorders
US20170296684A1 (en) * 2014-09-26 2017-10-19 The South African Nuclear Energy Corporation Limited Radiopharmaceutical conjugate
WO2020124237A1 (fr) * 2018-12-18 2020-06-25 Provincial Health Services Authority Composés théranostiques à double mode marqués au 18f et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206606A1 (en) * 2003-07-24 2011-08-25 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for preparation
US20150238641A1 (en) * 2012-09-13 2015-08-27 British Columbia Cancer Agency Branch Compositions targeting bradykinin receptor b1 for medical imaging of cancer and other disorders
US20170296684A1 (en) * 2014-09-26 2017-10-19 The South African Nuclear Energy Corporation Limited Radiopharmaceutical conjugate
WO2020124237A1 (fr) * 2018-12-18 2020-06-25 Provincial Health Services Authority Composés théranostiques à double mode marqués au 18f et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM [online] 3 October 2019 (2019-10-03), ANONYMOUS: "SID 385983309", XP093027939, retrieved from NCBI Database accession no. 385983309 *

Also Published As

Publication number Publication date
WO2022251516A2 (fr) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2021005808A (es) Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer.
MX2022008456A (es) Inhibidores de mek y usos terapeuticos de estos.
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
BR112022003165A2 (pt) Método de tratamento de cânceres associados a kras
CO2022014985A2 (es) Agentes para obtención de imágenes y radiofármacos dirigidos a la fap, y usos relacionados con los mismos
ZA202402726B (en) Dual-targeting compound and preparation method and application thereof
EA200500882A1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
WO2020132560A3 (fr) Compositions et méthodes pour cancérothérapie
WO2023158679A3 (fr) Composés inspirés de thiostrepton pour le traitement du cancer et leur préparation
WO2022251516A3 (fr) Complexes à chélateurs acycliques et leur utilisation en radiothérapie ciblée de cancer
MXPA04000407A (es) Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.
BG104933A (en) Water soluble azoles and broad-spectrum antifungals
Holmes et al. Estimating the excess lifetime risk of radiation induced secondary malignancy (SMN) in pediatric patients treated with craniospinal irradiation (CSI): Conventional radiation therapy versus helical intensity modulated radiation therapy
MX2022001678A (es) Derivados amidas hibridas de anfotericina b.
MX2021009206A (es) Terapias contra el cancer.
Xiao et al. Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes
MX2021013222A (es) Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
MX2018014167A (es) Tratamiento de lesiones de la piel.
NO20055888L (no) Kombinasjonsterapi
MX2022006608A (es) Nuevos inhibidores de aurora cinasa y uso de los mismos.
Sarria et al. Phase I/II study on kilovoltage surface brachytherapy in conjunctival cancer: preliminary results
Serkies et al. The feasibility study on continuous 7-day-a-week external beam irradiation in locally advanced cervical cancer: a report on acute toxicity

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22812174

Country of ref document: EP

Kind code of ref document: A2